{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:10:47Z","timestamp":1777893047801,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007859","name":"University of Kansas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007859","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cllc.2025.12.004","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:18:06Z","timestamp":1767745086000},"page":"98-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Randomized Phase II Trial of Hypo-fractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy\/Fraction Versus Standard- Fractionated IMRT, Concurrent With Carboplatin\/Paclitaxel and Followed by Consolidation Durvalumab, for Subjects With Stage III Non-Small Cell Lung Cancer"],"prefix":"10.1016","volume":"27","author":[{"given":"Krishna","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory N.","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.cllc.2025.12.004_bib0001","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.cllc.2025.12.004_bib0002","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.1999.17.9.2692","article-title":"Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer","volume":"17","author":"Furuse","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.12.004_bib0004","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cllc.2025.12.004_bib0005","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jrr\/rrac057","article-title":"Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer","volume":"64","author":"Kishi","year":"2023","journal-title":"J Radiat Res"},{"issue":"2","key":"10.1016\/j.cllc.2025.12.004_bib0006","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/j.ijrobp.2023.06.687","article-title":"Patterns of failure, volume of disease progression, and subsequent ablative management in locally advanced non-small cell lung cancer (LA-NSCLC) treated with definitive chemoradiation and consolidation immune checkpoint inhibitors (ICI)","volume":"117","author":"Friedes","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.cllc.2025.12.004_bib0007","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2025.12.004_bib0008","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non- small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.12.004_bib0009","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijrobp.2015.05.004","article-title":"Precision hypofractionated radiation therapy in poor performing patients with non-small cell lung cancer: phase 1 dose escalation trial","volume":"93","author":"Westover","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"34","key":"10.1016\/j.cllc.2025.12.004_bib0010","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1200\/JCO.2013.51.5353","article-title":"Dose-limiting toxicity after hypofractionated dose- escalated radiotherapy in non-small-cell lung cancer","volume":"31","author":"Cannon","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.12.004_bib0011","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/1748-717X-8-198","article-title":"High-dose accelerated hypofractionated three- dimensional conformal radiotherapy (at 3 Gy\/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small- cell lung cancer: a feasibility study","volume":"8","author":"Liu","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.cllc.2025.12.004_bib0012","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1748-717X-8-201","article-title":"Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy\/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial","volume":"8","author":"Lin","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.cllc.2025.12.004_bib0013","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12885-016-2314-1","article-title":"Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy\/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II trial","volume":"16","author":"Ren","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2025.12.004_bib0014","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fonc.2013.00286","article-title":"Moderately escalated hypofractionated (chemo) radiotherapy delivered with helical intensity-modulated technique in stage III unresectable non- small cell lung cancer","volume":"3","author":"Donato","year":"2013","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2025.12.004_bib0015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/COC.0000000000000140","article-title":"Dose-escalated hypofractionated intensity-modulated radiation therapy with concurrent chemotherapy for inoperable or unresectable non-small cell lung cancer","volume":"40","author":"Kim","year":"2017","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.12.004_bib0016","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.prro.2020.09.001","article-title":"Phase II study: the outcome of hypofractionated involved-field radiation therapy with concurrent chemotherapy for the treatment of locally advanced non-small cell lung cancer","volume":"11","author":"Katsuta","year":"2021","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.12.004_bib0017","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/10543400903280597","article-title":"Optimal designs for two-arm, phase II clinical trial design with multiple constraints","volume":"20","author":"Mayo","year":"2010","journal-title":"J Biopharm Stat"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425003328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425003328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:46:37Z","timestamp":1777617997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425003328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1525730425003328"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.12.004","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Phase II Trial of Hypo-fractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy\/Fraction Versus Standard- Fractionated IMRT, Concurrent With Carboplatin\/Paclitaxel and Followed by Consolidation Durvalumab, for Subjects With Stage III Non-Small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}